EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	("5739163").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/28 06:30
L2	2	("5523302").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/28 06:33
L3	6	"9736862"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/28 06:35
L4	2	("5773646").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/28 06:35
L5	18	("5523302").URPN.	USPAT	OR	ON	2007/06/28 08:52
L6	350	(562/431).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/28 08:53
L7	379	(562/471).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/28 08:54
L8	316	(562/472).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/06/28 08:54
L9	900	l6 or l7 or l8	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/28 08:54
L10	27582	williamson	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/28 08:55
L11	11	l9 and l10	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/06/28 08:55

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3	MAR 16	CASREACT coverage extended
NEWS 4	MAR 20	MARPAT now updated daily
NEWS 5	MAR 22	LWPI reloaded
NEWS 6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12	MAY 01	New CAS web site launched
NEWS 13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:02:47 ON 28 JUN 2007

=>
=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 06:02:58 ON 28 JUN 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0
DICTIONARY FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10563057\10563057 prod variant 1.str













chain nodes :
1 2 3 10 17 18 19 20 21 22 23 24 25 26 32
ring nodes :
4 5 6 7 8 9 11 12 13 14 15 16
chain bonds :
1-2 1-11 2-3 3-4 3-10 17-18 18-19 19-20 19-21 22-23 23-24 24-25 24-26
ring bonds :
4-5 4-9 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
3-10 17-18 18-19 19-20 19-21 22-23 23-24 24-25 24-26
exact bonds :
1-2 1-11 2-3 3-4
normalized bonds :
4-5 4-9 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15 15-16

```
G1:[*1],[*2]

Match level :
1:CLASS  2:CLASS  3:CLASS  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
 11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:CLASS  19:CLASS
 20:CLASS  21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  32:CLASS
33:Atom
Element Count :
Node 18: Limited
    C,C1-24

Node 23: Limited
    C,C1-24




L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> search l1 sss sam
SAMPLE SEARCH INITIATED 06:03:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1350 TO ITERATE

100.0% PROCESSED     1350 ITERATIONS                                  29 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        24796 TO    29204
PROJECTED ANSWERS:             257 TO      903

L2           29 SEA SSS SAM L1

=> d scan

L2   29 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   Acetic acid, [4-benzo[b]thien-2-yl-5-methoxy-2-[3-oxo-3-(5-quinolinyl)-1-
     propenyl]phenoxy]- (9CI)
MF   C29 H21 N O5 S
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10563057\10563057 ring isol prod variant 1.str













chain nodes :
1 2 3 10 17 18 19 20 21 22 23 24 25 26 32
ring nodes :
4 5 6 7 8 9 11 12 13 14 15 16
chain bonds :
1-2 1-11 2-3 3-4 3-10 17-18 18-19 19-20 19-21 22-23 23-24 24-25 24-26
ring bonds :
4-5 4-9 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
3-10 17-18 18-19 19-20 19-21 22-23 23-24 24-25 24-26
exact bonds :
1-2 1-11 2-3 3-4
normalized bonds :
4-5 4-9 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 4 : 11 :

```
G1:[*1],[*2]

Match level :
1:CLASS  2:CLASS  3:CLASS  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
 11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:CLASS  19:CLASS
 20:CLASS  21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  32:CLASS
33:Atom
Element Count :
Node 18: Limited
    C,C1-24

Node 23: Limited
    C,C1-24



L3      STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation..


=> search l3 sss sam
SAMPLE SEARCH INITIATED 06:06:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1350 TO ITERATE

100.0% PROCESSED     1350 ITERATIONS                                  26 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        24796 TO    29204
PROJECTED ANSWERS:             215 TO      825

L4           26 SEA SSS SAM L3

=> d scan

L4   26 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   Butanoic acid, 4-[2,6-dimethoxy-4-[3-(4-methoxyphenyl)-3-oxo-1-
     propenyl]phenoxy]-, ethenyl ester (9CI)
MF   C24 H26 O7
CI   COM
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10563057\10563057 PV 1.str













chain nodes :
1 2 3 10 17 18 19 20 21 22 23 24 25 26 32 35 36 37 38 39 40
ring nodes :
4 5 6 7 8 9 11 12 13 14 15 16
chain bonds :
1-2 1-11 2-3 3-4 3-10 17-18 18-19 19-20 19-21 20-35 22-23 23-24 24-25
24-26 25-36 35-37 35-38 36-39 36-40
ring bonds :
4-5 4-9 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
3-10 17-18 18-19 19-20 19-21 20-35 22-23 23-24 24-25 24-26 25-36
exact bonds :
1-2 1-11 2-3 3-4 35-37 35-38 36-39 36-40
normalized bonds :
4-5 4-9 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :

containing 4 : 11 :

G1:[*1],[*2]

Match level :
1:CLASS 2:CLASS 3:CLASS 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 32:CLASS
33:Atom 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
Element Count :
Node 18: Limited
C,C1-24

Node 23: Limited
C,C1-24

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> search l5 sss sam
SAMPLE SEARCH INITIATED 06:08:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 192 TO ITERATE

100.0% PROCESSED 192 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3009 TO 4671
PROJECTED ANSWERS: 4 TO 200

L6 4 SEA SSS SAM L5

=> d scan

L6 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 2-[4-[(1E)-3-[4-(hexylthio)-3,5-dimethylphenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI)
MF C33 H46 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L6 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 2-[4-[3-[4-(hexyloxy)-3,5-dimethylphenyl]-3-oxo-1-propenyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI)
MF C33 H46 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 2-[4-[(1E)-3-(4-chlorophenyl)-3-oxo-1-propen-1-yl]-2,6-dimethylphenoxy]-2-methyl-, 1-methylethyl ester
MF C24 H27 Cl O4

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 2-[3-(1,1-dimethylethyl)-2-hydroxy-5-[3-(2-hydroxyphenyl)-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-, 1-methylethyl ester
MF C26 H32 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.95	5.16

FILE 'CAPLUS' ENTERED AT 06:09:46 ON 28 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Jun 2007 VOL 147 ISS 1
FILE LAST UPDATED: 27 Jun 2007 (20070627/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> l6
L7 4 L6

=> d l7 1-4 ti fbib abs

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
TI Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients and their preparation, and use in the treatment of diseases
AN 2007:151078 CAPLUS
DN 146:229042

TI Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients and their preparation, and use in the treatment of diseases

IN Delhomel, Jean Francois; Caumont-Bertrand, Karine

PA Genfit, Fr.

SO U.S. Pat. Appl. Publ., 98pp., Cont.-in-part of U.S. Ser. No. 520,079.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2007032543	A1	20070208	US 2006-493040		20060726
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
				US 2005-520079	A2	20050422
	FR 2841900	A1	20040109	FR 2002-8571		20020708
	FR 2841900	B1	20070302			
	WO 2004005233	A1	20040115	WO 2003-FR2127		20030708
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				FR 2002-8571	A	20020708

PATENT FAMILY INFORMATION:

FAN 2004:19768

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	FR 2841900	A1	20040109	FR 2002-8571		20020708
	FR 2841900	B1	20070302			
	CA 2490986	A1	20040115	CA 2003-2490986		20030708
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	WO 2004005233	A1	20040115	WO 2003-FR2127		20030708
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				FR 2002-8571	A	20020708
	AU 2003264698	A1	20040123	AU 2003-264698		20030708
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	BR 2003012398	A	20050412	BR 2003-12398		20030708
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	EP 1525177	A1	20050427	EP 2003-762749		20030708
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	US 2005176808	A1	20050811	US 2003-520079		20030708

				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	CN 1668565	A	20050914	CN 2003-816366		20030708
				FR 2002-8571	A	20020708
	JP 2005532385	T	20051027	JP 2004-518890		20030708
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	NO 2004005301	A	20050204	NO 2004-5301		20041203
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	US 2007032543	A1	20070208	US 2006-493040		20060726
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
				US 2005-520079	A2	20050422

OS MARPAT 146:229042

GI



I



II

AB The invention concerns substituted 1,3-diphenylprop-2-en-1-one derivs. of formula I and combinations of said derivs. with other therapeutically active ingredients. The invention also concerns compns. comprising said derivs. or said combinations and uses thereof, for the treatment of cerebrovascular diseases, pathol. related to inflammation, neurodegeneration, deregulations of lipid and/or glucose metabolism, cell proliferation and/or differentiation and/or skin or central nervous system ageing. Compds. of formula I wherein X1 is H, halo, (un)substituted alkyl, OH and derivs., SH and derivs.; X3 is H, thionitroso, OH, alkylcarbonyloxy, alkyloxy, thio, alkylthio, alkylcarbonylthio, or O and S to form benzopyran derivative or benzothiopyran derivative; X3 - X5 are independently OH and derivs., SH and derivs., H, and (un)substituted alkyl; X6 is O, NH, and NOH and derivs.; and their optical and geometric isomers, racemates, tautomers, salts, hydrates, and mixts. thereof, are claimed. Example compound II was prepared by condensation of 4-[(ethoxycarbonyl)dimethylmethoxy]acetophenone with 3,5-di-tert-butyl-4-hydroxybenzaldehyde. All the invention compds. were evaluated for their

antioxidant properties, PPAR activation, antiinflammatory activity neuroprotective effect, lipid metabolism effect, and antidiabetic activity.

L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of 1,3-diphenyl-2-propen-1-one as PPAR activators, particularly agonists, and antioxidants and their pharmaceutical and cosmetic compositions
AN 2005:729631 CAPLUS
DN 143:193809
TI Preparation of 1,3-diphenyl-2-propen-1-one as PPAR activators, particularly agonists, and antioxidants and their pharmaceutical and cosmetic compositions
IN Caumont-Bertrand, Karine; Delhomel, Jean-Francois
PA Genfit, Fr.
SO PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2005073184	A1	20050811	WO 2005-FR40		20050107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
	FR 2864956	A1	20050715	FR 2004-123		20040108
	FR 2864956	B1	20060428			
	AU 2005209446	A1	20050811	AU 2005-209446		20050107
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
				WO 2005-FR40	W	20050107
	CA 2550576	A1	20050811	CA 2005-2550576		20050107
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
				WO 2005-FR40	W	20050107
	EP 1701938	A1	20060920	EP 2005-717386		20050107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
				WO 2005-FR40	W	20050107
	CN 1930122	A	20070314	CN 2005-80007226		20050107
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
				WO 2005-FR40	W	20050107
	BR 2005006718	A	20070502	BR 2005-6718		20050107
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
				WO 2005-FR40	W	20050107
	NO 2006002824	A	20061005	NO 2006-2824		20060616
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901

				WO 2005-FR40	W	20050107
	IN 2006DN03732	A	20070420	IN 2006-DN3732		20060629
				FR 2004-123	A	20040108
				WO 2005-FR40	W	20050107

PATENT FAMILY INFORMATION:

FAN 2005:610755

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	FR 2864956	A1	20050715	FR 2004-123		20040108
	FR 2864956	B1	20060428			
	AU 2005209446	A1	20050811	AU 2005-209446		20050107
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
				WO 2005-FR40	W	20050107
	CA 2550576	A1	20050811	CA 2005-2550576		20050107
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
				WO 2005-FR40	W	20050107
	WO 2005073184	A1	20050811	WO 2005-FR40		20050107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
	EP 1701938	A1	20060920	EP 2005-717386		20050107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
				WO 2005-FR40	W	20050107
	CN 1930122	A	20070314	CN 2005-80007226		20050107
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
				WO 2005-FR40	W	20050107
	BR 2005006718	A	20070502	BR 2005-6718		20050107
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
				WO 2005-FR40	W	20050107
	NO 2006002824	A	20061005	NO 2006-2824		20060616
				FR 2004-123	A	20040108
				FR 2004-9257	A	20040901
				WO 2005-FR40	W	20050107
	IN 2006DN03732	A	20070420	IN 2006-DN3732		20060629
				FR 2004-123	A	20040108
				WO 2005-FR40	W	20050107

OS MARPAT 143:193809

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X7 = (un)substituted O-alkyl, S-alkyl; X1-X5 =

independently halo, thionitroso, alkoxy, aryloxy, S-alkyl, etc.; X6, X8 = independently H, halo, alkoxy, etc.; with provisos; with the exclusion of certain compds.] were prepared as peroxisome proliferator-activated receptor agonists and antioxidants. Ten biol. examples are given. For example, (E)-II (m.p. = 177-179°) was prepared via condensation of 3,5-dimethyl-4-methylthioacetophenone (preparation given) with 3,5-dimethyl-4-hydroxybenzaldehyde, followed by O-alkylation of phenol with tert-Bu bromoisobutyrate and acidolysis of the ester. (E)-III displayed antioxidant properties as demonstrated by diminution of the production of conjugated dienes after Cu-induced LDL oxidation by 90%. (E)-II showed induced luciferase activity via PPARα/Gal4 transactivation with an induction factor of 17.05 at 1 μM. I are useful for treating cardiovascular diseases, dyslipidemia, syndrome X, diabetes, obesity, hypertension, inflammations, dermatol. diseases, cerebral ischemia and the disorders related tot he oxidative stress, for treating aging, in particular cutaneous aging.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of 1,3-diphenylprop-2-en-1-one as PPAR agonists and as antioxidants for treating cerebral ischemia and related diseases
AN 2004:19768 CAPLUS
DN 140:76897
TI Preparation of 1,3-diphenylprop-2-en-1-one as PPAR agonists and as antioxidants for treating cerebral ischemia and related diseases
IN Najib, Jamila; Caumont Bertrand, Karine
PA Genfit S.A., Fr.
SO Fr. Demande, 66 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	FR 2841900	A1	20040109	FR 2002-8571		20020708
	FR 2841900	B1	20070302			
	CA 2490986	A1	20040115	CA 2003-2490986		20030708
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	WO 2004005233	A1	20040115	WO 2003-FR2127		20030708
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				FR 2002-8571	A	20020708
	AU 2003264698	A1	20040123	AU 2003-264698		20030708
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	BR 2003012398	A	20050412	BR 2003-12398		20030708
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	EP 1525177	A1	20050427	EP 2003-762749		20030708
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708

US 2005176808	A1	20050811	US 2003-520079		20030708
			FR 2002-8571	A	20020708
			WO 2003-FR2127	W	20030708
CN 1668565	A	20050914	CN 2003-816366		20030708
			FR 2002-8571	A	20020708
JP 2005532385	T	20051027	JP 2004-518890		20030708
			FR 2002-8571	A	20020708
			WO 2003-FR2127	W	20030708
NO 2004005301	A	20050204	NO 2004-5301		20041203
			FR 2002-8571	A	20020708
			WO 2003-FR2127	W	20030708
US 2007032543	A1	20070208	US 2006-493040		20060726
			FR 2002-8571	A	20020708
			WO 2003-FR2127	W	20030708
			US 2005-520079	A2	20050422

PATENT FAMILY INFORMATION:

FAN 2007:151078

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2007032543	A1	20070208	US 2006-493040		20060726
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
				US 2005-520079	A2	20050422
	FR 2841900	A1	20040109	FR 2002-8571		20020708
	FR 2841900	B1	20070302			
	WO 2004005233	A1	20040115	WO 2003-FR2127		20030708
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				FR 2002-8571	A	20020708

OS MARPAT 140:76897

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X1 = halo, R1, G1R1; X2 = H, thionitroso, OH, alkylcarbonyloxy, alkyloxy, SH, alkylthio, alkylcarbonylthio or X2 = O or S that forms a 2-phenyl-4H-1-benzopyran-4-one with the carbon-3 of the propene chain; X3 = R3, G3R3; X4 = halo, thionitroso, R4, G4R4; X5 = R5, G5R5; X6 = O, NH and derivs.; R1, R3, R4, R5 = independently H, (un)substituted alkyl; G1, G3, G4, G5 = independently O or S; with at least one of X1, X3, X4, or X5 of formula GR and one of the R1, R3, R4, or R5 is a substituted radical, and that radical form a cycle, or is associated with a group G; their optical and geometrical isomers, racemates, tautomers, salts, hydrates and mixts.; with the exclusion of certain compds.] were prepared as peroxisome proliferator-activated receptors-α (PPARα) agonists and as antioxidants for treating cerebral ischemia and related diseases. For example, II was prepared by mixed-Aldol condensation of ketone III with 4-hydroxy-3,5-ditertbutylbenzaldehyde in the presence of ethanol/HCl. In an antioxidant test, selected I diminished the formation of oxidation product of LDL by AAPH by 33%. Selected I were PPARα agonists and showed induced luciferase activity via PPARα/Gal4 transactivation. I are

neuroprotectants useful for treating ischemia.
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
TI Composition based on substituted 1,3-diphenylprop-en-1-one derivatives, preparation and use as PPARα agonists, antioxidants as well as antiinflammatory agents
AN 2004:19750 CAPLUS
DN 140:76896
TI Composition based on substituted 1,3-diphenylprop-en-1-one derivatives, preparation and use as PPARα agonists, antioxidants as well as antiinflammatory agents
IN Najib, Jamila; Caumont Bertrand, Karine
PA Genfit S.A., Fr.
SO Fr. Demande, 66 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	FR 2841784	A1	20040109	FR 2002-8570		20020708
	FR 2841784	B1	20070302			
	CA 2490993	A1	20040115	CA 2003-2490993		20030708
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	WO 2004005243	A2	20040115	WO 2003-FR2128		20030708
	WO 2004005243	A3	20040422			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				FR 2002-8570	A	20020708
	AU 2003264699	A1	20040123	AU 2003-264699		20030708
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	EP 1519908	A2	20050406	EP 2003-762750		20030708
	EP 1519908	B1	20070613			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	BR 2003012399	A	20050412	BR 2003-12399		20030708
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	US 2005171149	A1	20050804	US 2005-520078		20030708
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	CN 1688532	A	20051026	CN 2003-816351		20030708
				FR 2002-8570	A	20020708
	JP 2005532386	T	20051027	JP 2004-518891		20030708
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	NO 2004005082	A	20041227	NO 2004-5082		20041122
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708

OS MARPAT 140:76896
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X1 = halo, R1, G1R1; X2 = H, thionitroso, OH, alkylcarbonyloxy, alkyloxy, SH, alkylthio, alkylcarbonylthio or X2 = O or S that forms a 2-phenyl-4H-1-benzopyran-4-one with the carbon-3 of the propene chain; X3 = R3, G3R3; X4 = halo, thionitroso, R4, G4R4; X5 = R5, G5R5; X6 = O, NH and derivs.; R1, R3, R4, R5 = independently H, (un)substituted alkyl; G1, G3, G4, G5 = independently O or S; with at least one of X1, X3, X4, or X5 of formula GR and one of the R1, R3, R4, or R5 is a substituted radical, and that radical form a cycle, or is associated with a group G; their optical and geometrical isomers, racemates, tautomers, salts, hydrates and mixts.; with the exclusion of certain compds.] were prepared as peroxisome proliferator-activated receptors-α (PPARα) agonists and as antioxidants for treating cerebral ischemia and related diseases. For example, II was prepared by mixed-Aldol condensation of ketone III with 4-hydroxy-3,5-ditertbutylbenzaldehyde in the presence of ethanol/HCl. In an antioxidant test, selected I (10-3 M) diminished the formation of oxidation product of LDL by AAPH by 33%. Selected I were PPARα agonists, showing induced luciferase activity via PPARα/Gal4 transactivation with a factor of induction ranging from 10 to 60, 5-50 and 3-35 at 100 μM, 30 μM, and 10 μM resp. I and their compns. are useful for treating cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative diseases, dermatol. and the disorders related to the oxydative stress, for preventing and treating aging, and in particular cutaneous aging.
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 06:02:47 ON 28 JUN 2007)

FILE 'REGISTRY' ENTERED AT 06:02:58 ON 28 JUN 2007
L1 STRUCTURE UPLOADED
L2 29 SEARCH L1 SSS SAM
L3 STRUCTURE UPLOADED
L4 26 SEARCH L3 SSS SAM
L5 STRUCTURE UPLOADED
L6 4 SEARCH L5 SSS SAM

FILE 'CAPLUS' ENTERED AT 06:09:46 ON 28 JUN 2007
L7 4 L6

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.99	40.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-3.12

FILE 'REGISTRY' ENTERED AT 06:13:20 ON 28 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0
DICTIONARY FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d his

     (FILE 'HOME' ENTERED AT 06:02:47 ON 28 JUN 2007)

     FILE 'REGISTRY' ENTERED AT 06:02:58 ON 28 JUN 2007
L1   STRUCTURE UPLOADED
L2   29 SEARCH L1 SSS SAM
L3   STRUCTURE UPLOADED
L4   26 SEARCH L3 SSS SAM
L5   STRUCTURE UPLOADED
L6   4 SEARCH L5 SSS SAM

     FILE 'CAPLUS' ENTERED AT 06:09:46 ON 28 JUN 2007
L7   4 L6

     FILE 'REGISTRY' ENTERED AT 06:13:20 ON 28 JUN 2007

=> search l5 sss full
FULL SEARCH INITIATED 06:13:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   4212 TO ITERATE

100.0% PROCESSED   4212 ITERATIONS   101 ANSWERS
SEARCH TIME: 00.00.01

L8   101 SEA SSS FUL L5

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary
files\10563057\10563057 PV 2.str








chain nodes :
1 2 3 10 17 18 19 20 21 22 23 24 25 26 32 35 36 37 38 39 40 41

ring nodes :
4 5 6 7 8 9 11 12 13 14 15 16
chain bonds :
1-2 1-11 2-3 3-4 3-10 17-18 18-19 19-20 19-21 20-36 22-23 23-24 24-25
24-26 25-39 36-37 36-38 39-40 39-41
ring bonds :
4-5 4-9 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
3-10 17-18 18-19 19-20 19-21 20-36 22-23 23-24 24-25 24-26 25-39
exact bonds :
1-2 1-11 2-3 3-4 36-37 36-38 39-40 39-41
normalized bonds :
4-5 4-9 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :

containing 4 : 11 :

G1:[*1],[*2]

Match level :
1:CLASS 2:CLASS 3:CLASS 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 32:CLASS
33:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS
Element Count :
Node 18: Limited
C,C1-24

Node 23: Limited
C,C1-24

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> search l9 sss sam
SAMPLE SEARCH INITIATED 06:14:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 192 TO ITERATE

100.0% PROCESSED 192 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3009 TO 4671
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9

=> search l9 sss full
FULL SEARCH INITIATED 06:14:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4212 TO ITERATE

100.0% PROCESSED 4212 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

L11 9 SEA SSS FUL L9

=> d scan

L11 9 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 2-[4-[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1-oxo-2-propen-1-yl]-3-hydroxyphenoxy]-2-methyl-, 1-methylethyl ester
MF C30 H40 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

L11 9 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 2-[3-hydroxy-4-[3-(4-hydroxy-3,5-dimethylphenyl)-1-oxo-2-propen-1-yl]phenoxy]-2-methyl-, 1-methylethyl ester
MF C24 H28 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 9 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetic acid, [3-[3-[3-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]-1-oxo-2-propenyl]phenoxy]-, 1,1-dimethylethyl ester (9CI)
MF C32 H41 N3 O8



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 9 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetic acid, [3-[3-(3-aminophenyl)-1-oxo-2-propenyl]phenoxy]-, 1,1-dimethylethyl ester (9CI)
MF C21 H23 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 9 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Oxiranepropanoic acid, α-[4-[1-oxo-3-[3-(phenylmethoxy)-4-propoxyphenyl]-2-propenyl]-3,5-bis(phenylmethoxy)phenoxy]-, 1,1-dimethylethyl ester (9CI)
MF C48 H50 O9



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 9 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 2-[4-[(2E)-3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1-oxo-2-propen-1-yl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester
MF C31 H42 O5

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 9 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 2-[3-hydroxy-4-[3-(4-hydroxy-3,5-dimethoxyphenyl)-1-oxo-2-propen-1-yl]phenoxy]-2-methyl-, 1-methylethyl ester
MF C24 H28 O8



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 9 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,3-Imidazolidinedicarboxylic acid, 2-[[3-[3-[3-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]-3-oxo-1-propenyl]phenyl]imino]-, bis(1,1-dimethylethyl) ester (9CI)
MF C34 H43 N3 O8



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 9 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetic acid, [3-[3-(3-nitrophenyl)-1-oxo-2-propenyl]phenoxy]-, 1,1-dimethylethyl ester (9CI)
MF C21 H21 N O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	344.65	384.80

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -3.12

FILE 'CAPLUS' ENTERED AT 06:15:16 ON 28 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 28 Jun 2007  VOL 147 ISS 1
FILE LAST UPDATED: 27 Jun 2007  (20070627/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 06:02:47 ON 28 JUN 2007)

     FILE 'REGISTRY' ENTERED AT 06:02:58 ON 28 JUN 2007
L1             STRUCTURE UPLOADED
L2          29 SEARCH L1 SSS SAM
L3             STRUCTURE UPLOADED
L4          26 SEARCH L3 SSS SAM
L5             STRUCTURE UPLOADED
L6           4 SEARCH L5 SSS SAM

     FILE 'CAPLUS' ENTERED AT 06:09:46 ON 28 JUN 2007
L7           4 L6

     FILE 'REGISTRY' ENTERED AT 06:13:20 ON 28 JUN 2007
L8         101 SEARCH L5 SSS FULL
L9             STRUCTURE UPLOADED
L10          0 SEARCH L9 SSS SAM
L11          9 SEARCH L9 SSS FULL

     FILE 'CAPLUS' ENTERED AT 06:15:16 ON 28 JUN 2007

=> l8
L12          8 L8

=> l11
L13          6 L11

=> save temp l12 pv1fnds/a
ANSWER SET L12 HAS BEEN SAVED AS 'PV1FNDS/A'

=> save temp l13 pv2fnds/a
ANSWER SET L13 HAS BEEN SAVED AS 'PV2FNDS/A'
```

=> l12 and l13
L14 3 L12 AND L13

=> d l14 1-3 ti fbib abs

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
TI Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients and their preparation, and use in the treatment of diseases
AN 2007:151078 CAPLUS
DN 146:229042
TI Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients and their preparation, and use in the treatment of diseases
IN Delhomel, Jean Francois; Caumont-Bertrand, Karine
PA Genfit, Fr.
SO U.S. Pat. Appl. Publ., 98pp., Cont.-in-part of U.S. Ser. No. 520,079.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI US 2007032543	A1	20070208	US 2006-493040		20060726
			FR 2002-8571	A	20020708
			WO 2003-FR2127	W	20030708
			US 2005-520079	A2	20050422
FR 2841900	A1	20040109	FR 2002-8571		20020708
FR 2841900	B1	20070302			
WO 2004005233	A1	20040115	WO 2003-FR2127		20030708

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			FR 2002-8571	A	20020708

PATENT FAMILY INFORMATION:
FAN 2004:19768

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI FR 2841900	A1	20040109	FR 2002-8571		20020708
FR 2841900	B1	20070302			
CA 2490986	A1	20040115	CA 2003-2490986		20030708
			FR 2002-8571	A	20020708
			WO 2003-FR2127	W	20030708
WO 2004005233	A1	20040115	WO 2003-FR2127		20030708

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			FR 2002-8571	A	20020708

AU 2003264698	A1	20040123	AU 2003-264698	20030708
			FR 2002-8571	A 20020708
			WO 2003-FR2127	W 20030708
BR 2003012398	A	20050412	BR 2003-12398	20030708
			FR 2002-8571	A 20020708
			WO 2003-FR2127	W 20030708
EP 1525177	A1	20050427	EP 2003-762749	20030708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			FR 2002-8571	A 20020708
			WO 2003-FR2127	W 20030708
US 2005176808	A1	20050811	US 2003-520079	20030708
			FR 2002-8571	A 20020708
			WO 2003-FR2127	W 20030708
CN 1668565	A	20050914	CN 2003-816366	20030708
			FR 2002-8571	A 20020708
JP 2005532385	T	20051027	JP 2004-518890	20030708
			FR 2002-8571	A 20020708
			WO 2003-FR2127	W 20030708
NO 2004005301	A	20050204	NO 2004-5301	20041203
			FR 2002-8571	A 20020708
			WO 2003-FR2127	W 20030708
US 2007032543	A1	20070208	US 2006-493040	20060726
			FR 2002-8571	A 20020708
			WO 2003-FR2127	W 20030708
			US 2005-520079	A2 20050422

OS MARPAT 146:229042

GI



I



II

AB The invention concerns substituted 1,3-diphenylprop-2-en-1-one derivs. of formula I and combinations of said derivs. with other therapeutically active ingredients. The invention also concerns compns. comprising said derivs. or said combinations and uses thereof, for the treatment of cerebrovascular diseases, pathol. related to inflammation,

neurodegeneration, deregulations of lipid and/or glucose metabolism, cell proliferation and/or differentiation and/or skin or central nervous system ageing. Compds. of formula I wherein X1 is H, halo, (un)substituted alkyl, OH and derivs., SH and derivs.; X3 is H, thionitroso, OH, alkylcarbonyloxy, alkyloxy, thio, alkylthio, alkylcarbonylthio, or O and S to form benzopyran derivative or benzothiopyran derivative; X3 - X5 are independently OH and derivs., SH and derivs., H, and (un)substituted alkyl; X6 is O, NH, and NOH and derivs.; and their optical and geometric isomers, racemates, tautomers, salts, hydrates, and mixts. thereof, are claimed. Example compound II was prepared by condensation of 4-[(ethoxycarbonyl)dimethylmethoxy]acetophenone with 3,5-di-tert-butyl-4-hydroxybenzaldehyde. All the invention compds. were evaluated for their antioxidant properties, PPAR activation, antiinflammatory activity neuroprotective effect, lipid metabolism effect, and antidiabetic activity.

L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of 1,3-diphenylprop-2-en-1-one as PPAR agonists and as antioxidants for treating cerebral ischemia and related diseases
AN 2004:19768 CAPLUS
DN 140:76897
TI Preparation of 1,3-diphenylprop-2-en-1-one as PPAR agonists and as antioxidants for treating cerebral ischemia and related diseases
IN Najib, Jamila; Caumont Bertrand, Karine
PA Genfit S.A., Fr.
SO Fr. Demande, 66 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	FR 2841900	A1	20040109	FR 2002-8571		20020708
	FR 2841900	B1	20070302			
	CA 2490986	A1	20040115	CA 2003-2490986		20030708
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	WO 2004005233	A1	20040115	WO 2003-FR2127		20030708
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				FR 2002-8571	A	20020708
	AU 2003264698	A1	20040123	AU 2003-264698		20030708
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	BR 2003012398	A	20050412	BR 2003-12398		20030708
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	EP 1525177	A1	20050427	EP 2003-762749		20030708
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	US 2005176808	A1	20050811	US 2003-520079		20030708
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
	CN 1668565	A	20050914	CN 2003-816366		20030708

			FR 2002-8571	A	20020708
JP 2005532385	T	20051027	JP 2004-518890		20030708
			FR 2002-8571	A	20020708
			WO 2003-FR2127	W	20030708
NO 2004005301	A	20050204	NO 2004-5301		20041203
			FR 2002-8571	A	20020708
			WO 2003-FR2127	W	20030708
US 2007032543	A1	20070208	US 2006-493040		20060726
			FR 2002-8571	A	20020708
			WO 2003-FR2127	W	20030708
			US 2005-520079	A2	20050422

PATENT FAMILY INFORMATION:

FAN 2007:151078

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2007032543	A1	20070208	US 2006-493040		20060726
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
				US 2005-520079	A2	20050422
	FR 2841900	A1	20040109	FR 2002-8571		20020708
	FR 2841900	B1	20070302			
	WO 2004005233	A1	20040115	WO 2003-FR2127		20030708

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	FR 2002-8571	A	20020708

OS MARPAT 140:76897

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X1 = halo, R1, G1R1; X2 = H, thionitroso, OH, alkylcarbonyloxy, alkyloxy, SH, alkylthio, alkylcarbonylthio or X2 = O or S that forms a 2-phenyl-4H-1-benzopyran-4-one with the carbon-3 of the propene chain; X3 = R3, G3R3; X4 = halo, thionitroso, R4, G4R4; X5 = R5, G5R5; X6 = O, NH and derivs.; R1, R3, R4, R5 = independently H, (un)substituted alkyl; G1, G3, G4, G5 = independently O or S; with at least one of X1, X3, X4, or X5 of formula GR and one of the R1, R3, R4, or R5 is a substituted radical, and that radical form a cycle, or is associated with a group G; their optical and geometrical isomers, racemates, tautomers, salts, hydrates and mixts.; with the exclusion of certain compds.] were prepared as peroxisome proliferator-activated receptors-α (PPARα) agonists and as antioxidants for treating cerebral ischemia and related diseases. For example, II was prepared by mixed-Aldol condensation of ketone III with 4-hydroxy-3,5-ditertbutylbenzaldehyde in the presence of ethanol/HCl. In an antioxidant test, selected I diminished the formation of oxidation product of LDL by AAPH by 33%. Selected I were PPARα agonists and showed induced luciferase activity via PPARα/Gal4 transactivation. I are neuroprotectants useful for treating ischemia.

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
TI Composition based on substituted 1,3-diphenylprop-en-1-one derivatives, preparation and use as PPARα agonists, antioxidants as well as antiinflammatory agents
AN 2004:19750 CAPLUS
DN 140:76896
TI Composition based on substituted 1,3-diphenylprop-en-1-one derivatives, preparation and use as PPARα agonists, antioxidants as well as antiinflammatory agents
IN Najib, Jamila; Caumont Bertrand, Karine
PA Genfit S.A., Fr.
SO Fr. Demande, 66 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	FR 2841784	A1	20040109	FR 2002-8570		20020708
	FR 2841784	B1	20070302			
	CA 2490993	A1	20040115	CA 2003-2490993		20030708
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	WO 2004005243	A2	20040115	WO 2003-FR2128		20030708
	WO 2004005243	A3	20040422			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				FR 2002-8570	A	20020708
	AU 2003264699	A1	20040123	AU 2003-264699		20030708
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	EP 1519908	A2	20050406	EP 2003-762750		20030708
	EP 1519908	B1	20070613			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	BR 2003012399	A	20050412	BR 2003-12399		20030708
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	US 2005171149	A1	20050804	US 2005-520078		20030708
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	CN 1688532	A	20051026	CN 2003-816351		20030708
				FR 2002-8570	A	20020708
	JP 2005532386	T	20051027	JP 2004-518891		20030708
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	NO 2004005082	A	20041227	NO 2004-5082		20041122
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708

OS MARPAT 140:76896
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X1 = halo, R1, G1R1; X2 = H, thionitroso, OH, alkylcarbonyloxy, alkyloxy, SH, alkylthio, alkylcarbonylthio or X2 = O or S that forms a 2-phenyl-4H-1-benzopyran-4-one with the carbon-3 of the propene chain; X3 = R3, G3R3; X4 = halo, thionitroso, R4, G4R4; X5 = R5, G5R5; X6 = O, NH and derivs.; R1, R3, R4, R5 = independently H, (un)substituted alkyl; G1, G3, G4, G5 = independently O or S; with at least one of X1, X3, X4, or X5 of formula GR and one of the R1, R3, R4, or R5 is a substituted radical, and that radical form a cycle, or is associated with a group G; their optical and geometrical isomers, racemates, tautomers, salts, hydrates and mixts.; with the exclusion of certain compds.] were prepared as peroxisome proliferator-activated receptors-α (PPARα) agonists and as antioxidants for treating cerebral ischemia and related diseases. For example, II was prepared by mixed-Aldol condensation of ketone III with 4-hydroxy-3,5-ditertbutylbenzaldehyde in the presence of ethanol/HCl. In an antioxidant test, selected I (10-3 M) diminished the formation of oxidation product of LDL by AAPH by 33%. Selected I were PPARα agonists, showing induced luciferase activity via PPARα/Gal4 transactivation with a factor of induction ranging from 10 to 60, 5-50 and 3-35 at 100 μM, 30 μM, and 10 μM resp. I and their compns. are useful for treating cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative diseases, dermatol. and the disorders related to the oxydative stress, for preventing and treating aging, and in particular cutaneous aging.

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> williamson
L15 1593 WILLIAMSON

=> l12 or l13
L16 11 L12 OR L13

=> l15 and l16
L17 0 L15 AND L16

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	29.10	413.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-5.46

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:21:21 ON 28 JUN 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

```
PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 06:24:10 ON 28 JUN 2007
FILE 'CAPLUS' ENTERED AT 06:24:10 ON 28 JUN 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      29.10     413.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.34      -5.46

=> d his

     (FILE 'HOME' ENTERED AT 06:02:47 ON 28 JUN 2007)

     FILE 'REGISTRY' ENTERED AT 06:02:58 ON 28 JUN 2007
L1                STRUCTURE UPLOADED
L2             29 SEARCH L1 SSS SAM
L3                STRUCTURE UPLOADED
L4             26 SEARCH L3 SSS SAM
L5                STRUCTURE UPLOADED
L6              4 SEARCH L5 SSS SAM

     FILE 'CAPLUS' ENTERED AT 06:09:46 ON 28 JUN 2007
L7              4 L6

     FILE 'REGISTRY' ENTERED AT 06:13:20 ON 28 JUN 2007
L8            101 SEARCH L5 SSS FULL
L9                STRUCTURE UPLOADED
L10             0 SEARCH L9 SSS SAM
L11             9 SEARCH L9 SSS FULL

     FILE 'CAPLUS' ENTERED AT 06:15:16 ON 28 JUN 2007
L12             8 L8
L13             6 L11
                  SAVE TEMP L12 PV1FNDS/A
                  SAVE TEMP L13 PV2FNDS/A
L14             3 L12 AND L13
L15          1593 WILLIAMSON
L16            11 L12 OR L13
L17             0 L15 AND L16

=> d l16 5-11 ti fbib abs

L16  ANSWER 5 OF 11  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Preparation of 1,3-diphenylprop-2-en-1-one as PPAR agonists and as
     antioxidants for treating cerebral ischemia and related diseases
AN   2004:19768  CAPLUS
DN   140:76897
TI   Preparation of 1,3-diphenylprop-2-en-1-one as PPAR agonists and as
     antioxidants for treating cerebral ischemia and related diseases
IN   Najib, Jamila; Caumont Bertrand, Karine
PA   Genfit S.A., Fr.
SO   Fr. Demande, 66 pp.
     CODEN: FRXXBL
DT   Patent
LA   French
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
```

PI FR 2841900 A1 20040109 FR 2002-8571 20020708
FR 2841900 B1 20070302
CA 2490986 A1 20040115 CA 2003-2490986 20030708
FR 2002-8571 A 20020708
WO 2003-FR2127 W 20030708
WO 2004005233 A1 20040115 WO 2003-FR2127 20030708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
FR 2002-8571 A 20020708
AU 2003264698 A1 20040123 AU 2003-264698 20030708
FR 2002-8571 A 20020708
WO 2003-FR2127 W 20030708
BR 2003012398 A 20050412 BR 2003-12398 20030708
FR 2002-8571 A 20020708
WO 2003-FR2127 W 20030708
EP 1525177 A1 20050427 EP 2003-762749 20030708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
FR 2002-8571 A 20020708
WO 2003-FR2127 W 20030708
US 2005176808 A1 20050811 US 2003-520079 20030708
FR 2002-8571 A 20020708
WO 2003-FR2127 W 20030708
CN 1668565 A 20050914 CN 2003-816366 20030708
FR 2002-8571 A 20020708
JP 2005532385 T 20051027 JP 2004-518890 20030708
FR 2002-8571 A 20020708
WO 2003-FR2127 W 20030708
NO 2004005301 A 20050204 NO 2004-5301 20041203
FR 2002-8571 A 20020708
WO 2003-FR2127 W 20030708
US 2007032543 A1 20070208 US 2006-493040 20060726
FR 2002-8571 A 20020708
WO 2003-FR2127 W 20030708
US 2005-520079 A2 20050422

PATENT FAMILY INFORMATION:
FAN 2007:151078

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2007032543	A1	20070208	US 2006-493040		20060726
				FR 2002-8571	A	20020708
				WO 2003-FR2127	W	20030708
				US 2005-520079	A2	20050422
	FR 2841900	A1	20040109	FR 2002-8571		20020708
	FR 2841900	B1	20070302			
	WO 2004005233	A1	20040115	WO 2003-FR2127		20030708

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
FR 2002-8571 A 20020708

OS MARPAT 140:76897
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X1 = halo, R1, G1R1; X2 = H, thionitroso, OH, alkylcarbonyloxy, alkyloxy, SH, alkylthio, alkylcarbonylthio or X2 = O or S that forms a 2-phenyl-4H-1-benzopyran-4-one with the carbon-3 of the propene chain; X3 = R3, G3R3; X4 = halo, thionitroso, R4, G4R4; X5 = R5, G5R5; X6 = O, NH and derivs.; R1, R3, R4, R5 = independently H, (un)substituted alkyl; G1, G3, G4, G5 = independently O or S; with at least one of X1, X3, X4, or X5 of formula GR and one of the R1, R3, R4, or R5 is a substituted radical, and that radical form a cycle, or is associated with a group G; their optical and geometrical isomers, racemates, tautomers, salts, hydrates and mixts.; with the exclusion of certain compds.] were prepared as peroxisome proliferator-activated receptors-α (PPARα) agonists and as antioxidants for treating cerebral ischemia and related diseases. For example, II was prepared by mixed-Aldol condensation of ketone III with 4-hydroxy-3,5-ditertbutylbenzaldehyde in the presence of ethanol/HCl. In an antioxidant test, selected I diminished the formation of oxidation product of LDL by AAPH by 33%. Selected I were PPARα agonists and showed induced luciferase activity via PPARα/Gal4 transactivation. I are neuroprotectants useful for treating ischemia.
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
TI Composition based on substituted 1,3-diphenylprop-en-1-one derivatives, preparation and use as PPARα agonists, antioxidants as well as antiinflammatory agents
AN 2004:19750 CAPLUS
DN 140:76896
TI Composition based on substituted 1,3-diphenylprop-en-1-one derivatives, preparation and use as PPARα agonists, antioxidants as well as antiinflammatory agents
IN Najib, Jamila; Caumont Bertrand, Karine
PA Genfit S.A., Fr.
SO Fr. Demande, 66 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	FR 2841784	A1	20040109	FR 2002-8570		20020708
	FR 2841784	B1	20070302			
	CA 2490993	A1	20040115	CA 2003-2490993		20030708
				FR 2002-8570	A	20020708
				WO 2003-FR2128	W	20030708
	WO 2004005243	A2	20040115	WO 2003-FR2128		20030708
	WO 2004005243	A3	20040422			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				FR 2002-8570	A 20020708
AU 2003264699	A1	20040123	AU 2003-264699		20030708
			FR 2002-8570	A	20020708
			WO 2003-FR2128	W	20030708
EP 1519908	A2	20050406	EP 2003-762750		20030708
EP 1519908	B1	20070613			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

				FR 2002-8570	A 20020708
				WO 2003-FR2128	W 20030708
BR 2003012399	A	20050412	BR 2003-12399		20030708
			FR 2002-8570	A	20020708
			WO 2003-FR2128	W	20030708
US 2005171149	A1	20050804	US 2005-520078		20030708
			FR 2002-8570	A	20020708
			WO 2003-FR2128	W	20030708
CN 1688532	A	20051026	CN 2003-816351		20030708
			FR 2002-8570	A	20020708
JP 2005532386	T	20051027	JP 2004-518891		20030708
			FR 2002-8570	A	20020708
			WO 2003-FR2128	W	20030708
NO 2004005082	A	20041227	NO 2004-5082		20041122
			FR 2002-8570	A	20020708
			WO 2003-FR2128	W	20030708

OS MARPAT 140:76896
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X1 = halo, R1, G1R1; X2 = H, thionitroso, OH, alkylcarbonyloxy, alkyloxy, SH, alkylthio, alkylcarbonylthio or X2 = O or S that forms a 2-phenyl-4H-1-benzopyran-4-one with the carbon-3 of the propene chain; X3 = R3, G3R3; X4 = halo, thionitroso, R4, G4R4; X5 = R5, G5R5; X6 = O, NH and derivs.; R1, R3, R4, R5 = independently H, (un)substituted alkyl; G1, G3, G4, G5 = independently O or S; with at least one of X1, X3, X4, or X5 of formula GR and one of the R1, R3, R4, or R5 is a substituted radical, and that radical form a cycle, or is associated with a group G; their optical and geometrical isomers, racemates, tautomers, salts, hydrates and mixts.; with the exclusion of certain compds.] were prepared as peroxisome proliferator-activated receptors-α (PPARα) agonists and as antioxidants for treating cerebral ischemia and related diseases. For example, II was prepared by mixed-Aldol condensation of ketone III with 4-hydroxy-3,5-ditertbutylbenzaldehyde in the presence of ethanol/HCl. In an antioxidant test, selected I (10-3 M) diminished the formation of oxidation product of LDL by AAPH by 33%. Selected I were PPARα agonists, showing induced luciferase activity via PPARα/Gal4 transactivation with a factor of induction ranging from 10 to 60, 5-50 and 3-35 at 100 μM, 30 μM, and 10 μM resp. I and their compns. are useful for treating cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative diseases, dermatol. and the disorders related to the oxydative stress, for preventing and treating aging, and in particular cutaneous aging.

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of 3-guanidinophenylamides and related compounds as integrin αvβ3 inhibitors or antagonists.
AN 1998:430106 CAPLUS
DN 129:108912
TI Preparation of 3-guanidinophenylamides and related compounds as integrin αvβ3 inhibitors or antagonists.
IN Chandrakumar, Nizal; Chen, Barbara B.; Chen, Helen Y.; Clare, Michael; Gasiecki, Alan F.; Haack, Richard A.; Malecha, James W.; Ruminski, Peter G.; Russell, Mark A.
PA G.D. Searle and Co., USA
SO U.S., 77 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5773646	A	19980630	US 1997-825086	19970327
			US 1997-825086	19970327

OS MARPAT 129:108912
GI



I

AB Title compds. [I; A = NR5C(Y1)NR7R8, etc.; Y1 = NR2, O, S; R2 = H, alkyl, aryl, OH, alkoxy, cyano, NO2, amino, aminocarbonyl, alkenyl, alkynyl, (substituted) alkyl, aryl, heterocyclyl; R2R7 = (substituted) heterocyclyl; R7, R8 = H, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, bicycloalkyl, aryl, acyl, benzoyl, (substituted) alkyl, heterocyclyl, etc.; NR7R8 = (substituted) mono- or bicyclic heterocyclyl; R5 = H, alkyl, alkenyl, alkynyl, PhCH2, PhCH2CH2; Z1, Z2, Z4, Z5 = H, alkyl, OH, alkoxy, aryloxy, aralkoxy, halo, haloalkyl, haloalkoxy, NO2, amino, aminoalkyl, alkylamino, dialkylamino, cyano, alkylthio, alkylsulfonyl, carboxyl derivs., (fused) aryl; cycloalkyl, (fused) heterocyclyl, A; B = SO2NR50, CONR50(CH2)p, CH2O, SOCH2, SO2CH2, etc.; p = 0-2; R50 = H, alkyl; Y = (CHR70)q, O; q = 0, 1; R70 = H, alkyl, (substituted) aryl; m = 0-2; R = XR3; X = O, S, NR4; R3, R4 = H, alkyl, alkenyl, alkynyl, halolalkyl, aryl, aralkyl, etc.; Y3, Z3 = H, alkyl, aryl, cycloalkyl, aralkyl; R1 = H, alkyl, aryl, etc.], were prepared Thus, 3-[[[3-[(aminomiminomethyl)amino]phenyl]sulfonyl]amino]-β-phenylbenzenepropanoic acid trifluoroacetate (preparation given) inhibited vitronectin adhesion with IC50 = 16.7 nM.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of meta-substituted phenylene derivatives and their use as αvβ3 integrin antagonists or inhibitors
AN 1997:679052 CAPLUS
DN 127:318772
TI Preparation of meta-substituted phenylene derivatives and their use as αvβ3 integrin antagonists or inhibitors
IN Chandrakumar, Nizal; Chen, Barbara B.; Chen, Helen; Clare, Michael; Gasiecki, Alan F.; Haack, Richard A.; Malecha, James W.; et al.

PA G.D. Searle and Co., USA; Chandrakumar, Nizal; Chen, Barbara B.; Chen, Helen; Clare, Michael; Gasiecki, Alan F.

SO PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 9736862	A1	19971009	WO 1997-US4461		19970326
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
				US 1996-14464P	P	19960329
	CA 2250464	A1	19971009	CA 1997-2250464		19970326
				US 1996-14464P	P	19960329
	AU 9723370	A	19971022	AU 1997-23370		19970326
				US 1996-14464P	P	19960329
				WO 1997-US4461	W	19970326
	EP 889877	A1	19990113	EP 1997-916110		19970326
	EP 889877	B1	20010829			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
				US 1996-14464P	P	19960329
				WO 1997-US4461	W	19970326
	JP 2000506538	T	20000530	JP 1997-535309		19970326
				US 1996-14464P	P	19960329
				WO 1997-US4461	W	19970326
	AT 204857	T	20010915	AT 1997-916110		19970326
				US 1996-14464P	P	19960329
				WO 1997-US4461	W	19970326
	ES 2162676	T3	20020101	ES 1997-916110		19970326
				US 1996-14464P	P	19960329

OS MARPAT 127:318772

GI



I



II

Q= 

AB The present invention relates to a class of compds., i.e, phenylalkanoic acid and phenoxyacetic acid derivs., represented by formula [I; A = (un)substituted NHC(:NH)NH, NHCONH, NHC(:S)NH, or NHCH:NH, C(:NH)NH2, C(:NOH)NH2; Z1 - Z5 = H, alkyl, OH, alkoxy, aryloxy, aralkoxy, halo, haloalkyl, haloalkoxy, NO2, NH2, aminoalkyl, alkylamino, dialkylamino, cyano, etc.; B = N-(un)substituted CONH(CH2)p or SO2NH, NHCONH(CH2)p, CO2(CH2)p, CH2CH2, alkenylene or alkynylene optionally substituted by oxo, CH2O, SCH2, SOCH2, SO2 CH2, CH(OH)CH2O, CH:CHCO; wherein p = 0, 1,2; Y = (un)substituted (CH2)q, O; q = 0,1; m = 0, 1,2; R = X-R3; wherein X = O, S, (un)substituted NH; R3 = H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, aralkyl, sugar or steroid residue; Y3, Z3 = H, alkyl, aryl, cycloalkyl, aralkyl; R1 = H, alkyl, aryl, NHCOR51, NHCO2R12, NHCOR12, NHSO2R12, NHCONHR12; wherein R12 = H, alkyl, cycloalkyl, aralkyl, aryl; R51 = N-substituted pyrrolidinyl, piperidinyl, or morpholinyl] or pharmaceutically acceptable salts thereof are prepared Also claimed are pharmaceutical compns. comprising above compds. I and methods of selectively inhibiting or antagonizing αvβ3 integrin. A method for treating conditions mediated by αvβ3 integrin, e.g. tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, in a mammal comprises administering an effective αvβ3 integrin-inhibiting amount of above compds. I. Thus, 3-(3-aminobenzenesulfonamido)-3-phenylpropanoic acid derivative (II; R10 = H) was condensed with N,N'-bis(tert-butoxycarbonyl)-2-(1H)-tetrahydropyrimidinethione followed by deprotection to give II (R10 = Q), which showed IC50 of 0.75 nM for 50% inhibition of the maximum binding of biotinylated vitronectin to human vitronectin receptor (αvβ3) purified from human placenta (Niiya et al., Blood, 1987).

L16 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
TI Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
AN 1996:392101 CAPLUS
DN 125:96084
TI Aromatic compounds containing basic and acidic termini useful as

fibrinogen receptor antagonists
IN Cain, Gary A.; Eyermann, Charles J.
PA Du Pont Merck Pharmaceutical Co., USA
SO U.S., 43 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5523302	A	19960604	US 1993-157860	19931124
US 5739163	A	19980414	US 1996-612597	19960308
			US 1993-157860 A3	19931124

OS MARPAT 125:96084
AB This invention relates to novel compds. containing basic and acidic termini, pharmaceutical compns. containing such compds., processes for preparing such compds., and methods of using these compds., alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

L16 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
TI Studies on anti-allergic agent. I. 1,2,3-Trisubstituted 2-propen-1-one derivatives, 3,4-disubstituted 4-oxo-2-butenoic acids and the related compounds.
AN 1991:207137 CAPLUS
DN 114:207137
TI Studies on anti-allergic agent. I. 1,2,3-Trisubstituted 2-propen-1-one derivatives, 3,4-disubstituted 4-oxo-2-butenoic acids and the related compounds.
AU Hirao, Hirohiko; Fujita, Takayuki; Iwasaki, Yoshiya; Ide, Hisao; Inoue, Sachiko; Kitagawa, Koki; Futaki, Shiroh; Kawanishi, Hirofumi; Akita, Tadashi
CS Shikoku Chem. Co., Ltd., Tokushima, 771-02, Japan
SO Yakugaku Zasshi (1990), 110(10), 727-36
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal
LA Japanese
GI



I



II

AB A new series of trisubstituted propenone derivs. (I; X = CH, N; R = 2-, 3-, 4-Cl, 4-Br, F, OMe, OEt, OPh, Ph, H; Y = CO, CHOH; R1 = dialkylaminoethoxy, alkylcarbomethoxy) and disubstituted oxobutenoic acids (II; R2 = H, alkyl; R3 = H, Ph, OPh, alkoxy, F, Cl, Br) were synthesized. Inhibitory activities against rat passive cutaneous anaphylaxis (PCA) reaction and histamine release from rat mast cells were tested. The ester derivs. (I; R = 4-Cl; R1 = alkylcarbomethoxy) and (II; R2 = alkyl) exhibited a more potent inhibitory activity against histamine release compared with the other derivs., but were somewhat weaker in their anti-PCA activity. Structure-activity relationships were discussed.

L16 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
TI Dihydrochalcone sweeteners. A study of the atypical temporal phenomena
AN 1981:137933 CAPLUS
DN 94:137933
TI Dihydrochalcone sweeteners. A study of the atypical temporal phenomena
AU DuBois, Grant E.; Crosby, Guy A.; Stephenson, Rebecca A.
CS Chem. Synth. Lab., Dynapol, Palo Alto, CA, 94304, USA
SO Journal of Medicinal Chemistry (1981), 24(4), 408-28
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI



II, R=$COCH_2CO_2H$, X=Na

III, R=$CH_2CH_2PO_3H_2$, X=K

IV, R=CH_2NHSO_3H, X=K

V, R=$CH_2CH(OH)CO_2H$, X=Na

AB Neohesperidin dihydrochalcone (I) [20702-77-6] has 340 times the sweetness of sucrose, but is not much used as a sweetener because of its poor temporal properties, i.e. the sweetness is slow to develop in the mouth and there is a prolonged, unpleasant aftertaste. Forty-four analogs of I were synthesized and tested to determine whether the temporal properties of I were due to metabolism, conformation, chelation, or hydrophobicity. None of these possibilities were strongly supported. Four of the analogs, II [76799-09-2], III [76799-10-5], IV [70412-97-4], and V [76799-11-6] were 280-440 times sweeter than sucrose and may be useful in some food systems. However, their temporal taste characteristics were no better than those of I.

=>
=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.02	453.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.80	-10.92

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:41:03 ON 28 JUN 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 06:51:55 ON 28 JUN 2007
FILE 'CAPLUS' ENTERED AT 06:51:55 ON 28 JUN 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.02	453.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.80	-10.92

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.02	453.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.80	-10.92

FILE 'REGISTRY' ENTERED AT 06:52:07 ON 28 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0
DICTIONARY FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	454.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.92

FILE 'REGISTRY' ENTERED AT 06:52:32 ON 28 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0
DICTIONARY FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10563057\10563057 SM halide.str





chain nodes :
1 2 3 4 5 6 8 9
chain bonds :
1-2 2-3 3-4 3-6 4-5 5-8 5-9
exact/norm bonds :
1-2 2-3 3-4 3-6 4-5
exact bonds :
5-8 5-9

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 8:CLASS 9:CLASS
Element Count :
Node 2: Limited
C,C1-24

L18 STRUCTURE UPLOADED

=> d l18
L18 HAS NO ANSWERS
L18 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l18 sss sam
SAMPLE SEARCH INITIATED 06:53:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 77460 TO ITERATE

2.6% PROCESSED 2000 ITERATIONS 24 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 1532643 TO 1565757
PROJECTED ANSWERS: 16761 TO 20419

L19 24 SEA SSS SAM L18

=> d scan

L19 24 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetic acid, α-methoxy-α-(trifluoromethyl)-,
1-(2-methoxy-2-oxoethyl)-9-propyl-1,9-nonanediyl ester,
[1S-[1R*(S*),9R*(S*)]]- (9CI)
MF C35 H44 F6 O8

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.35	455.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE 0.00 -10.92

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:54:30 ON 28 JUN 2007